By summarizing these reported DCC mutations (Fig. 3), we observed that the majority of documented DCC mutations (53%) manifest as MRMVs, with 7% of carriers reported to have a combination of ACC and MRMVs. Here, DCC is linked to adrenal cortex carcinoma.